Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
bluebird bio
3203
bluebird bio
Technology
Biotechnology
bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.
Suggest edits
Founded
1992
Raised
$384.3M
Follow us
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Biogen
Xconomy
HubSpot
Money Mover
Formlabs
Akamai
General Catalyst
Companies in the same industry
MedDay
IDP Pharma
Galena Biopharma
Clearside BioMedical, Inc.
Engender Technology
Mersana Therapeutics
Arkis BioSciences
AFFiRiS AG
Movetis
Sernova Corp.
Alexa global traffic share
Twitter followers
Overview
Funding
5
Add info
Latest funding
Show all
$250,000,000
Post-IPO equity - 2016
$9,300,000
Venture capital - 2012
California Institute for Regenerative Medicine
Team Size
50+
Employees
I work here
Location
Cambridge
,
United States
Headquarters
Explore Cambridge
Pulse 2.0
bluebird bio (BLUE) Stock Price: Why It Surged Over 70% Today
Pulse 2.0
bluebird bio (BLUE) Stock Price: Why It Increased 21.14%
Pulse 2.0
bluebird bio (BLUE) Stock: $10 Price Target And Neutral Rating
MedCity News
bluebird bio's stock tanks after report of serious toxicity in sickle cell patient
$250,000,000
Post-IPO equity
Twitter
Boston Business on Twitter
The Motley Fool
Better Buy: Agenus Inc. vs. bluebird bio
The Motley Fool
Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today
The Motley Fool
Better Buy: bluebird bio vs. Inovio Pharmaceuticals
The Motley Fool
Better Buy: Juno Therapeutics vs. bluebird bio
The Motley Fool
bluebird bio Inc: Catnapping in Cambridge
The Motley Fool
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
The Motley Fool
bluebird bio, Inc. Takes Flight Towards First Approval
The Motley Fool
Here's Why bluebird bio.'s Stock Tumbled in March
The Motley Fool
Why bluebird bio's Stock Jumped 12.9% on Wednesday
The Motley Fool
Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals
The Motley Fool
Why Bluebird Bio Inc. Plunged Today
The Motley Fool
Why bluebird bio Inc Presented a Lower Price Today
The Motley Fool
Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today
Stock markets
The Motley Fool
Why bluebird bio Inc.'s Stock Dropped 34% in January
Stock markets
The Motley Fool
bluebird bio Inc. Takes Flight
Stock markets
Health
